Metastasis is the primary cause of cancer-related death in oncology patients. A comprehensive understanding of the molecular mechanisms that cancer cells usurp to promote metastatic dissemination is critical for the development and implementation of novel diagnostic and treatment strategies. Here we show that the membrane protein RECK (Reversion-inducing cysteine-rich protein with kazal motifs) controls breast cancer metastasis by modulating a novel, non-canonical and convergent signal transducer and activator of transcription factor 3 (STAT3)-dependent angiogenic program. Neoangiogenesis and STAT3 hyperactivation are known to be fundamentally important for metastasis, but the root molecular initiators of these phenotypes are poorly understood. Our study identifies loss of RECK as a critical and previously unknown trigger for these hallmarks of metastasis. Using multiple xenograft mouse models, we comprehensively show that RECK inhibits metastasis, concomitant with a suppression of neoangiogenesis at secondary sites, while leaving primary tumor growth unaffected. Further, with functional genomics and biochemical dissection we demonstrate that RECK controls this angiogenic rheostat through a novel complex with cell surface receptors to regulate STAT3 activation, cytokine signaling, and the induction of both vascular endothelial growth factor and urokinase plasminogen activator. In accordance with these findings, inhibition of STAT3 can rescue this phenotype both in vitro and in vivo. Taken together, our study uncovers, for the first time, that RECK is a novel regulator of multiple well-established and robust mediators of metastasis; thus, RECK is a keystone protein that may be exploited in a clinical setting to target metastatic disease from multiple angles.
INTRODUCTION
Breast cancer is one of the most common cancers among women, causing over 400 000 deaths annually worldwide. 1 Metastatic disease is a major cause of morbidity and mortality and is currently incurable, making it a primary obstacle to improving breast cancer outcomes. 2 The molecular basis of metastasis remains incompletely understood. In recent years, a number of metastasis-suppressor genes (MSGs) have been discovered. These genes are defined by their specific ability to inhibit metastasis without altering primary tumor growth. Both preclinical models and retrospective human studies suggest that MSGs have key roles in controlling the development of metastasis. 3 Elucidating the molecular mechanisms by which these genes control the metastatic process offers valuable insight into tumor biology and may lead to new therapeutic options.
Reversion-inducing cysteine-rich protein with kazal motifs (RECK) is a putative MSG that is implicated in tumor progression. 4 RECK is a membrane-anchored protein that is involved in several physiological processes, including regulation of extracellular matrix (ECM) integrity, vascular growth during development and stabilization of tissue architecture. 5, 6 In some cell systems, RECK can influence matrix metalloproteinase (MMP) function. 7 RECK expression is frequently silenced in tumor cells. 8, 9 Interestingly, a recent study focusing on genome-wide DNA methylation profiling of CpG islands in breast cancer identified the RECK gene as a common target of promoter hypermethylation. 10 Despite documented effects of RECK on the behavior of tumor cells, the signaling pathways targeted by RECK and the specific mechanism by which RECK modulates metastasis remain elusive. Furthermore, while RECK-mediated invasion has been largely attributed to changes in MMP expression in vitro, most tumors and tumor cell lines express extremely low levels of MMPs, suggesting that additional mechanisms are likely at play. 11, 12 In this study, we apply a systematic, multifaceted strategy using human tumor samples, in vivo metastasis models and multiple, unbiased high throughput analyses to provide a comprehensive analysis of the role of RECK during breast cancer metastasis. We generated new data sets that include large number of patient samples and used them to illustrate a relationship between RECK expression and disease-specific survival. Furthermore, analyses of matched pairs of primary human breast tumors and distant metastases reveal that RECK expression is further silenced during metastatic progression. We demonstrate using multiple mouse models that RECK reconstitution in vivo suppresses tumor metastases. Using several unbiased screens, we have identified novel pathways and binding partners that directly mediate the effects of RECK on metastasis. Finally, we show that RECK controls these phenotypes through signal transducer and activator of transcription factor 3 (STAT3)-dependent regulation of an angiogenic program.
RESULTS

Analysis of matched lymph node and distant metastases demonstrates that RECK expression is downregulated during metastatic breast cancer progression
We first sought to explore whether RECK expression was lost specifically during metastatic progression or whether the process of RECK silencing was already completed in the primary tumor. To answer this question, we first evaluated RECK gene expression in 36 primary tumors and lymph node metastasis pairs. Microarray analysis of these tumors revealed a significant decrease in RECK expression in metastatic lymph nodes compared with matched primary tumors in luminal A, luminal B and Her 2 subytpes (P = 0.0009, Figure 1a ). These results were confirmed by qunatitative reverse transcriptase-PCR (qRT-PCR; P o0.01, Supplementary Figure S1A ). Interestingly, we did not see a significant difference in RECK expression in the basal subtype ( Figure 1a) ; however, the baseline expression of RECK in our basal primary tumors was already considerably lower than other subtypes (Supplementary Figure S1B ). This is not seen with other larger patient cohorts, suggesting that there may be significant diversity in RECK expression between different basal tumors.
We next wanted to determine whether the RECK silencing was also evident in distant metastases. We performed immunohistochemistry (IHC) for RECK on 43 matched primary breast tumors and distant metastatic lesions (including the lung, liver and bone) and scored the staining intensity. Distant metastases had significantly decreased RECK expression compared with matched primary tumors (P = 0.001, Figure 1b , Supplementary Figure S1C and D). Together, these data show that RECK expression is lost in many tumors during progression from primary tumor to metastasis, consistent with a role for RECK in protecting against metastatic breast cancer.
RECK does not alter cell proliferation and loss of RECK alone is not sufficient to achieve cellular transformation As RECK expression is low in most solid tumor cell lines, we next investigated the effects of reconstituting RECK expression (by constitutively expressing RECK via lentiviral transduction) in three highly invasive breast cancer cell lines (MDA-MB-231, LM2-4175 and BOM1-1833). RECK expression was confirmed by western blotting (Figure 2a ), and proper membrane localization was visualized by immunocytochemistry and confocal microscopy ( Figure 2b ). Altered RECK expression did not change the rate of cell growth in vitro (Figures 2c-e) nor did it result in cell cycle changes (Figures 2f-h). Given that RECK expression is lower in clinical tumor specimens compared with normal breast tissue, we next sought to examine whether loss of RECK is sufficient for malignant transformation. Stable knockdown of RECK did not transform normal human mammary epithelial cells (HMECs) in xenograft assays (Figures 2i-k) . These results suggest that RECK loss is not sufficient to result in transformation or altered cell division but instead may act via other mechanisms.
RECK suppresses vascular endothelial growth factor (VEGF) expression, endothelial recruitment in metastatic lesions and metastatic burden in vivo We next examined whether reconstituting RECK could reduce metastatic burden in an in vivo model of metastasis. Accordingly, we stably expressed RECK in LM2-4175 cells (an in vivo selected and highly lung metastatic cell line) 13, 14 and injected them into the lateral tail vein of athymic nude mice. Bioluminescent imaging (BLI) of mice re-expressing RECK revealed a significant decrease in metastatic tumor burden compared with empty vector (EV) control (Figures 3a and b ). Given that a significant difference in metastatic burden was first evident via BLI at 4 weeks postintravenous injection (Figure 3b ), we harvested lung tissue from each group at this time point for detailed analysis. Consistent with the BLI data at 4 weeks, hematoxylin and eosin (H&E) staining of lung tissue ( Figure 3c ) revealed a significant decrease in tumor burden ( Figure 3d ) and the number of metastatic foci ( Figure 3e ) in mice injected with cells re-expressing RECK.
RECK has been previously suggested to have a role in vascular organization. 7 Therefore, we stained lung tissue for CD34 and VEGF. RECK-expressing metastatic foci had significantly less CD34 staining (Figures 3c and f), suggesting that RECK suppresses de novo blood vessel formation or recruitment. This phenotype was concomitant with decreased VEGF (Figures 3c and g) and Ki67 expression ( Figures 3c and h) , demonstrating that RECK may interfere with metastatic outgrowth by reducing vascularization. A decrease in metastasis in vivo was also observed after intracardiac injection of BOM1-1833 cells (an in vivo selected and highly bone metastatic cell line) 13 re-expressing RECK (Figures 3i and j) .
RECK has been hypothesized to act in part through MMP-2, MMP-9 and MT1-MMP in some cell systems. [15] [16] [17] Interestingly, in our breast metastatic model, immunostaining of metastatic nodules for MMP2-MMP-9 and MT1-MMP revealed no significant changes in expression ( Supplementary Figure S2A -C). However, as immunostaining does not discriminate between latent and active MMP-2 and MMP-9, we cannot discount the possibility that there may be differences in MMP activity. Nevertheless, MMP-2 and MMP-9 were undetectable in conditioned media from MDA-MB-231, LM2-4175 and BOM1-1833 by enzyme-linked immunosorbent assay (ELISA; data not shown), suggesting that any differences seen in vivo are likely from changes in secretion of these proteins from surrounding stroma and not from the tumor cells themselves. Together, these data suggest that the phenotypic effects of RECK expression in breast cancer metastases may involve novel mechanisms independent of MMPs.
Coordinate control of a cooperative neovascularization program by RECK via regulation of endothelial remodeling and multiple secreted regulators of angiogenesis In order to gain further insight into the molecular changes associated with RECK expression, we analyzed the transcriptomes of MDA-MB-231 and LM2-4175 cells overexpressing RECK. Ingenuity pathway analysis of differentially expressed genes between control and RECK-overexpressing cells (Supplementary Tables S1 and S2) revealed significant alterations in IL-6, IL-8 and IL-10 signaling pathways in both cell lines (Figures 4a and b,  Supplementary Tables S5 and S6 ). In addition, VEGF and hypoxiainducible factor-1α signaling pathways were also altered in MDA-MB-231 and LM2-4175 cells, respectively. All of these pathways are intimately involved in the regulation of angiogenesis, consistent with our hypothesis that RECK can control transcriptional programs that influence tumor neovascularization. [18] [19] [20] We next asked whether reconstituting RECK was sufficient to alter VEGF secretion or endothelial cell phenotypes in vitro. ELISAs were performed on conditioned media from MDA-MB-231, LM2-4175 and BOM1-1833 cells re-expressing RECK, and all were found to secrete significantly less VEGF compared with their respective controls ( Figure 4c ). In addition, conditioned media from MDA-MB-231 and LM2-4175 cells re-expressing RECK inhibited chemotaxis of endothelial cells using Boyden transwell assays (Figures 4d and e ). Importantly, this phenotype was rescued with the addition of recombinant VEGF. Furthermore, conditioned media from MDA-MB-231 and LM2-4175 cells re-expressing RECK significantly reduced endothelial cell tube formation in vitro (Figures 4f and g) , showing that RECK can regulate endothelial organization. These data suggest that RECK may be an important modulator of tumor-mediated angiogenesis, consistent with the changes observed in vivo.
To determine whether there are other potential angiogenic factors besides VEGF that are altered by RECK, we performed an antibody array screen of 55 known pro-or anti-angiogenic factors, including various ECM components, proteases, growth factors and signaling molecules. LM2-4175 cells expressing either RECK or EV were subject to a low oxygen challenge (0.5% O 2 ) to mimic the hypoxic tumor environment and stimulate release of angiogenic factors. After 24 h, conditioned media was isolated from both cell lines and screened with the array. Strikingly, the array revealed that reconstituting RECK coordinately suppressed many pro-angiogenic factors and increased the secretion of antiangiogenic factors (Figures 4h and i). For example, reconstituting RECK potently suppressed the secretion of urokinase plasminogen activator (uPA), a major modulator of extracellular proteolysis and angiogenesis and a known mediator of breast cancer metastasis. 21 We confirmed RECK-mediated suppression of uPA secretion by ELISA in three breast cancer cell lines (Figure 4j A spontaneous metastasis assay reveals that RECK suppresses metastasis in part through negative regulation of uPA Given our finding that RECK modulates the secretion of uPA, a well-documented protein involved in ECM proteolysis and breast cancer metastasis, we next wanted to determine whether reconstituting RECK in breast cancer cells could suppress spontaneous metastasis in vivo. Metastasis is a multistep process, including initial invasion of surrounding tissue, intravasation/ extravasation and survival and outgrowth at secondary sites. 22 Although frequently modeled using tail vein injection, metastasis modeled via orthotopic injection may more accurately recapitulate the steps necessary for metastasis. MDA-MB-231 cells expressing either EV or RECK were orthotopically injected into the mammary fat pad of NOD/SCID/IL2Rγ-deficient (NSG) mice. Consistent with our in vitro proliferation results, primary tumor volume was unchanged following RECK re-expression ( Figure 5a ). BLI of mice at day 40 revealed a significant decrease in spontaneous metastasis from tumors expressing high RECK vs control (Figures 5b and c), which was confirmed by H&E staining and quantification of tumor burden in the lung and liver (Figures 5d and e). IHC was used to confirm that RECK expression was high in primary tumors with reconstituted RECK at day 40 ( Figure 5f ). Furthermore, IHC for uPA in primary tumors re-expressing RECK revealed a significant decrease in uPA staining intensity compared with controls ( Figure 5g ), again suggesting a strong relationship between RECK, uPA and metastasis. 
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Depletion of RECK promotes a uPA-dependent invasion and pro-angiogenic program
To evaluate the effect of RECK perturbation on VEGF and uPA, we knocked down RECK in the breast cancer cell lines Hs343T and Hs606T. We chose these cell lines as they have significant endogenous levels of RECK expression (Cancer Cell Line Encyclopedia, Broad, Supplementary Figure S3 ). Hs343T and Hs606T cells were transfected with scramble (control) or RECK small interfering RNA (siRNA). RECK knockdown was confirmed by western blotting (Figure 6a ). Consistent with our RECK re-expression experiments, RECK knockdown had no significant effect on the growth of cells. Representative growth curves from Hs606T cells are shown in Figure 6b . ELISA performed on conditioned media isolated from these cells demonstrated that RECK knockdown results in a significant increase in VEGF and uPA secretion (Figures 6c and e ).
These changes were concurrent with changes in VEGF and PLAU gene expression ( Figures 6d and f) . Furthermore, using a Matrigel transwell invasion assay, we revealed that RECK knockdown significantly increased invasion of both Hs343T and Hs606T lines and that this was rescued by concomitant knockdown of uPA (siPLAU Figures 6g and h ). This suggests that the increased invasive potential associated with the loss of RECK could be, in part, due to increases in uPA secretion. Finally, to test the effects of RECK loss on angiogenic markers, we repeated the angiogenesis protein array using conditioned media from Hs606T cells transfected with either scramble (control) or RECK siRNA. Consistent with previous results, RECK knockdown resulted in high levels of pro-angiogenic factors in conditioned media, including VEGF and uPA, and reduced levels of anti-angiogenic factors (Figures 6i and j) . RECK associates with multiple cell surface receptors, modulates cytokine signaling and activates STAT3 signaling To further dissect the details of the signaling pathways that underlie the effects of RECK, we tested the results of RECK knockdown on global gene expression in Hs343T and Hs606T cells ( Supplementary Tables S3 and S4 ). Microarray and ingenuity pathway analysis analyses revealed that IL-6, IL-8, L10 and Janus-activated kinase/STAT signaling pathways were significantly altered in response to RECK knockdown in both the cell lines tested (Figures 7a and b , Supplementary Tables S7 and S8 ). Importantly, these data are consistent with pathways altered by reconstituting RECK in previous experiments (Figures 4a and b , Supplementary Tables S1).
Given that RECK is a glycosylphosphatidylinisotol-anchored membrane protein, we hypothesized that RECK may be altering signaling pathways by directly binding other membrane proteins, extracellular cytokines or proteases. To test this, we modified a receptor antibody array to screen for potential RECK binding partners. RECK-immunoprecipitated lysate from Hs606T cells was used to probe a panel of 119 soluble extracellular or membranebound proteins. Immunoprecipitation revealed that RECK bound to IL-8, β1-integrin and galectin-1 (Figure 7c ). As a positive control, we confirmed RECK binding in this modified system and by conventional western blotting (Figures 7c and d) . We validated the interaction screen by immunoblot for β1-integrin and galectin-1 ( Figure 7d ). As one of the most significantly altered pathways common to all microarray analysis was IL-6 signaling, we next determined that RECK also directly complexes with IL-6RA and gp130, the principle mechanism of IL-6 signaling in breast cancer (Figure 7d ). 23 Finally, we identified that RECK also binds to the uPA receptor uPAR (Figure 7d ), providing a possible additional mechanism for RECK-mediated suppression of uPA activity.
To characterize RECK-induced signaling events in the cytoplasm, we used a phospho-protein array and compared lysate from MDA-MB-231+EV and MDA-MB-231+RECK cells. RECK expression results in decreased phosphorylation of a number or growth-related oncoproteins. Among the most significantly downregulated phospho-proteins was pSTAT3. RECK expression resulted in a loss of phosphorylation on the activating Y705 residue (Supplementary Figure S4A) . Interestingly, this is consistent with our protein and microarray results, as pSTAT3 is a welldescribed downstream effector of IL-6 and IL-8 and is capable of inducing both VEGF and uPA. [24] [25] [26] [27] We confirmed that pSTAT3 is regulated by RECK using a doxycycline-inducible construct, showing that RECK induction resulted in significantly decreased pSTAT3 levels (Figure 7e ). Furthermore, even under hypoxic conditions, which are known to potently activate STAT3 via phosphorylation, 28, 29 pSTAT3 was suppressed upon RECK reconstitution in LM2-4175 cells (Figure 7f ). Consistent with these data, knockdown of RECK with siRNA in Hs343T and Hs606T cells resulted in increased pSTAT3 (Figures 7g and h) . Modulation of metastasis and angiogenesis by RECK is dependent on STAT3 signaling We next investigated whether the effects of RECK on angiogenesis, invasion and metastasis are STAT3 dependent. First, we determined that the increase in HS606T invasion caused by RECK knockdown was attenuated with the concurrent knockdown of STAT3, demonstrating that RECK-mediated invasiveness is, in part, mediated by STAT3 (Figure 7i, Supplementary Figure S4B ). In addition, increased VEGF secretion conferred by RECK knockdown was also attenuated following concurrent knockdown of STAT3 (Figure 7j ). This shows that, like the invasion phenotype, RECK-mediated VEGF secretion is also due, at least in part, to STAT3 activation. Finally, we determined whether exogenously expressing STAT3 can reverse the ability of RECK to suppress metastasis. For this, we again made use of our in vivo metastasis model. LM2-4175 cells that stably overexpressed RECK were transduced with STAT3 and injected into the mammary fat pad of NSG mice (spontaneous metastasis model). BLI and histological analysis of lung metastasis at day 30 revealed decreased metastasis in mice with cells expressing RECK alone, as expected (Figures 7k and l) . This phenotype was attenuated with the concomitant expression of STAT3, suggesting that STAT3 is downstream of RECK and that metastatic suppressive activity of RECK is mediated by STAT3. Using our tail vein in vivo metastasis assay and these cells, we found that mice injected with cells expressing RECK has a significant survival advantage that was abrogated by co-expression of STAT3 and RECK (P = 0.023, Figure 7m ). Together, these results demonstrate that the invasive and angiogenic phenotypes that result from RECK suppression are mediated through STAT3 signaling.
Suppression of RECK expression is associated with poor survival in human breast cancer
Finally, we sought to validate the association of RECK expression with breast cancer survival outcomes and to determine the relationship of RECK loss with pathological covariates. Previous studies linking RECK with clinical outcomes used relatively small numbers of samples. We dichotomized 1586 breast cancer patients from the Curtis data set 30 into 'RECK high' and 'RECK low' groups based on median RECK expression and analyzed disease-specific survival. Here, high RECK expression conferred a significant survival advantage (P = 0.025, Figure 8a ). This was confirmed in two independent, large breast cancer data sets using identical methodology (P = 0.006, Figure 8b ,Supplementary Figure  S5A ). Due to the unique size of the Curtis data set, we were able to further categorize RECK expression as 'normal' or 'low,' based on values in normal breast tissue (Supplementary Figure S5B) . Here, 'low' is defined as having an outlier level of RECK expression below the 10th percentile of RECK expression in normal breast tissue. Patients with primary tumors harboring normal RECK expression experienced significantly superior survival compared with those with tumors bearing low RECK (P = 0.000083, Figure 8c ).
In addition to poorer survival, we found that higher primary tumor grade, cellularity and size were also significantly associated with low RECK expression (Figures 8d-f ). RECK expression was not significantly associated with estrogen receptor, progesterone receptor or HER2 status in the Curtis or TCGA breast cancer cohorts (Figures 8g-i, Supplementary Figure S5C-E) . Notably, the expression of RECK was significantly decreased in all breast cancer subtypes compared with normal breast tissue (Figures 8j and k,  Supplementary Figures S5F and G) , suggesting that loss of RECK expression can occur across all breast cancer types. Together these results demonstrate that RECK expression is an important determinant of breast cancer survival, that decreased RECK expression is associated with aggressive tumor characteristics and that RECK alteration is likely selected for in cancers.
DISCUSSION
RECK is recognized as a frequently inactivated metastasis suppressor in a number of human malignancies. Although loss of RECK has been linked to aggressive tumor behavior and metastasis, the molecular mechanisms by which RECK affects these processes is incompletely understood. The effect of RECK on tumor cells has been thought to be attributable to changes in MMP activity. However, in most tumors, these proteases are not predominantly produced by the malignant cells themselves but instead by adjacent stroma. 31 Furthermore, MMP levels in our in vivo tumor models do not significantly associate with RECK expression. Accordingly, our data here suggest that, at least in metastatic progression, RECK functions by associating with a number of receptors that signal through STAT3, modulating STAT3 signaling and promoting the coordinated expression of a multifaceted invasion and angiogenic program. As RECK is known to have key roles in normal development, 32, 33 we reveal a molecular framework for how RECK regulates metastasis and highlight how metastatic cells can usurp RECK-dependent processes to promote tumor cell survival at distant sites.
We established a significant relationship between RECK expression and disease-specific survival in breast cancer. Through the use of matched pairs of primary human breast tumors and both distant and lymph node metastasis, we show that RECK expression is suppressed in metastatic lesions compared with primary tumors. This is critical as it demonstrates that loss of RECK in metastases is not simply due to sporadic differences between primary tumors but occurs during metastatic progression. Furthermore, as tumor heterogeneity often exists within breast tumors, it would be interesting to determine whether cells with the lowest levels of RECK expression within an individual primary tumor are in fact the founder cells in distant metastases.
Preclinical data and retrospective human studies suggest that MSGs have the potential to improve patient selection for therapy and may predict response to treatment. 34 For example, mechanistic insights into the function of the MSG NM23 have led to the development of novel treatment strategies both exploiting aberrant NM23-associated cell signaling and reconstituting NM23 itself. Clinical trials using NM23 as an anti-metastasis therapy are currently underway. 3 Notably, it has been shown in vitro that treating cell lines harboring epigenetically silenced RECK with HDAC or DNA methyltransferase inhibitors can lead to the re-expression of RECK. 35, 36 In our study, RECK reconstitution in breast cancer cells significantly decreased metastatic burden in multiple in vivo models of metastasis. As such, it may be reasonable to explore new treatment strategies aimed at treating tumors with RECK silencing with epigenetically targeted therapies.
RECK not only affects invasive potential of cancer cells but its loss also supports the survival and expansion of tumor cells in distant organs and tissues. Angiogenesis is a hallmark of cancer, wound healing and various ischemic and inflammatory diseases 37, 38 VEGF is a potent inducer of angiogenesis and lymphangiogenesisand is a highly specific mitogen for endothelial cells. 39 Here, we reveal that RECK directly modulates VEGF secretion. Furthermore, RECK convergently regulates multiple pro-and anti-angiogenic factors in a coordinated fashion. These data therefore provide detailed mechanistic insights into the RECK-mediated angiogenic phenotype. 40 Our data reveal that RECK functions by regulating STAT3 activity. STAT3 activation has been linked to VEGF expression and oncogenesis, but the mechanisms underlying this hyperactivity are not well understood. 41, 42 Two primary transcription factors that directly regulate VEGF expression are STAT3 and hypoxiainducible factor-1α. 43 Induction of VEGF can be achieved by these transcription factors through diverse stimuli, including hypoxia and cytokines. Our data show that RECK binds to many receptors that are known activators of STAT3 signaling and angiogenesis, including IL-8, galectin-1, B1-integrin, uPAR and the primary activators of STAT3 signaling in breast cancer, IL-6RA and gp130. 23, [44] [45] [46] [47] [48] Interestingly, it has previously been reported that the inhibition of gp130 signaling in breast cancer blocks STAT3 activation, inhibiting malignancy in vivo. 49 It seems that RECK has a central role in coordinating and downregulating the extent of STAT3 activation downstream of these various receptors. This activity, in turn, regulates neovascular programs that are important for metastases. Of note, STAT3 can be activated by phosphorylation at Y705 and/or S727. pSTAT3-Y705, which was assessed in this study, is the STAT3 phosphorylation site that is associated with IL-6 and IL-8 signaling. 50, 51 In contrast, STAT3-S727 phosphorylation is associated with cellular proliferation via extracellular signal-regulated kinase signaling and has been shown to inversely correlate with pSTAT3-Y705 levels. [52] [53] [54] [55] Here we show that RECK knockdown results in increased pSTAT3-Y705 and decreased pSTAT3-S727 ( Supplementary Figures S6A and B) . This further supports our model of RECK-mediated STAT3 regulation of metastatic processes via inhibition of IL-mediated STAT3 phosphorylation. Interestingly, studies focusing on microRNA expression and metastasis have revealed that STAT3 can control microRNAs, which in turn regulates RECK expression. 56 These data combined with the findings in our study point to a feedback loop between RECK, STAT3 and microRNAs. Of note, our study did not see changes in tumorigenecity or primary tumor growth by directly modulating RECK expression. In contrast, studies on microRNAs that modulate RECK do report changes in tumorigenecity, suggesting that RECK expression is just one of the many potential targets of microRNAs. 57 In our study, we showed that RECK mediated suppression of spontaneous metastasis in vivo, which suggests that RECK can affect multiple steps in the metastatic process. Interestingly, RECK suppression was concomitant with increased expression of uPA, a known inducer of breast cancer metastasis. In vitro, it has been shown that uPA itself has the capacity to increase the invasiveness of tumor cells, 58 which we have confirmed here using breast cancer cell lines. The uPA system is a serine protease family that includes uPA, uPAR and plasminogen activator inhibitors. 59 uPA catalyzes the activation of plasminogen to plasmin, which degrades the ECM and basement membranes either directly or indirectly through activating pro-MMPs (as most MMPs are secreted as latent zymogens). 60, 61 This uPA-RECK relationship may partially explain how most tumors and tumor cell lines secrete very low levels of MMPs, yet retain strong invasive potential. Although MMPs have a clear role in metastasis, in vivo studies are complicated owing to the presence of both inactive and active MMPs, whose conversion is catalyzed by other proteases. Further, the cellular origin of secreted MMPs in vivo is difficult to ascertain. As a result, we cannot exclude the importance of MMPs in our study, though our discovery of RECK-mediated uPA secretion provides both complimentary (uPA-induced MMP activation) and alternative (direct ECM proteolysis) mechanisms of RECK-associated suppression of metastasis.
In summary, RECK is a multifunctional and broadly important MSG that is frequently suppressed in cancer. Our observations address several ill-defined issues central to the development of metastasis: how a frequently inactivated MSG suppresses metastases, how metastases activate neovascular programs, what signaling mechanisms underlie RECK's control of angiogenesis, and the molecular causes of STAT3 hyperactivity in metastatic lesions. Our work provides critical insights into our understanding of the metastatic process.
MATERIALS AND METHODS Expression data sets
The van de Vijver 62 and Stockholm 63 breast cancer data sets were downloaded from the Gene Expression Omnibus (GEO http://www.ncbi. nlm.nih.gov/geo). The Curtis data set 30 and the TCGA breast cancer data set 64 were downloaded from http://www.oncomine.org.
Primary human breast cancer and matched lymph node metastases
Paired primary tumor and lymph node metastases were collected during surgical resection. All tissue was used with informed consent and banked at Memorial Sloan-Kettering Cancer Center (MSKCC) in accordance with IRB approval. All samples were snap-frozen and stored at − 80°C until use. All samples were H&E stained and independently reviewed by a breast cancer pathologist. Tumors were microdissected to obtain 470% purity. RNA was isolated from fresh frozen samples using the RNEasy Plus mini prep kit (Qiagen, Valencia, CA, USA). Nucleic acid quality was determined with the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Primary tumor and matched metastasis pairs, for which RNA of sufficient quantity and quality was available, were analyzed on Affymetrix GeneChip Human Genome U133 2.0 Array (Affymetrix, Santa Clara, CA, USA) at the genomics core at Sloan-Kettering Institute according to the manufacturer's protocol.
Primary human breast cancer and matched distant metastases
Paired primary tumor and distant metastases were collected with informed consent and banked at MSKCC in accordance with IRB approval. All samples were formalin fixed and paraffin embedded until use. All samples were H&E stained and independently reviewed by a breast cancer pathologist. Samples were also sectioned (5 μm) and immunostained with a RECK antibody and blindly scored.
Microarray analysis of cell lines
Total RNA was isolated from cell lines using the RNEasy Plus mini prep kit (Qiagen). Nucleic acid quality was determined with the Agilent 2100 Bioanalyzer. Samples were analyzed on Affymetrix GeneChip Human Genome U133 2.0 Array at the genomics core at Sloan-Kettering Institute according to the manufacturer's protocol.
Gene expression microarray analysis
Gene expression analysis in cell lines was performed with the Human Genome U133A 2.0 microarray (Affymetrix). CEL files were imported into the Partek Genomics Suite software and normalized using robust multiarray average quartile normalization and log probe summarization. Differentially expressed genes were identified by analysis of variance. Genes that were differentially expressed at Po0.05 and had at least an absolute value of 1.2 × fold change (1.5-fold change for Hs343T) were considered significant. Enriched pathways were identified in the differentially expressed genes in Ingenuity pathway analysis (Ingenuity Systems, Valencia, CA, USA) and determined significant at − log2(P-value)41.3 ( Supplementary Tables S5-S8 ).
Animal studies
All animal work was done in accordance with the Institutional Animal Care and Use Committee at MSKCC. Athymic Nu/Nu mice were obtained from Harlan Laboratories (Indianapolis, IN, USA) and NSG mice were obtained from Jackson Laboratories (Bar Harbor, ME, USA). All animals were injected between 5 and 7 weeks of age. Intracardiac injections of BOM1-1833 cells and intravenous injections of LM2-4175 cells were performed as previously described. 13, 14 Single-cell suspensions of the indicated cell lines (1 × 10 6 cells) in 1:1 serum-free media/Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) were injected orthotopically into the mammary fat pad of 6-week-old female NSG mice. Animals were imaged weekly via BLI (IVIS, Xenogen, Alameda, CA, USA).
Cell lines
Hs606T, Hs343T, human umbilical vein endothelial cells (HUVEC), HEK293T and HMEC-hTERT were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured according to ATCC's recommended conditions. MDA-MB-231, LM2-4175 and BOM1-1833 were all generous gifts from Dr Joan Massague (Memorial Sloan-Kettering Cancer Center, New York, NY, USA) and were cultured as described previously. 13, 14 Cell proliferation assay In all, 1 × 10 5 cells were plated in 6-cm plates in triplicate, and cell numbers were counted at the indicated days using a ViCELL cell counter (Beckman, Indianapolis, IN, USA).
Cell cycle analysis
Cells were trypsinized, fixed with ice cold 70% ethanol and stained using 7-AAD. Cell cycle analysis was performed on a FACSCalibur (BD Biosciences). Analysis was performed using the FlowJo software (Flowjo, Ashland, OR, USA), and cell cycle quantification was performed using the Watson (Pragmatic) model.
Immunoblotting
Cell lysates were prepared with CellLytic M (Sigma, St Louis, MO, USA) containing protease and phosphotase inhibitor (Thermo Scientific, Pittsburgh, PA, USA). Debris was removed via centrifugation for 10 min at 14 000 r.p.m. in an Eppendorf Centrifuge 5424C (Eppendorf, Hauppauge, NY, USA) at 4°C. Protein concentrations were determined by BCA protein assay kit (Thermo Scientific), and equal amounts of protein samples were loaded on NuPAGE Bis-Tris 4-12% sodium dodecyl sulfate gels (Invitrogen, Grand Island, NY, USA) and blotted onto polyvinylidene difluoride membrane (Millipore, Billerica, MA, USA). Imaging was performed on a FujiFilm LAS4000 (GE Healthcare, Pittsburgh, PA, USA) . All blots were repeated three times, and representative images were chosen for publication.
Chemotaxis assay
Conditioned media from the indicated cell types was placed in the bottom chamber of a 12-well plate. HUVEC cells were seeded at a density of 5 × 10 4 /well in transwell inserts placed in the upper chamber (8 μm, BD Biosciences). After incubation for 12 h, migrated cells were quantified by counting on a Nikon TE2000E brightfield microscope, Nikon Instruments, Melville, NY, USA).
ELISA
All ELISA kits were purchased from R&D Systems (Minneapolis, MN, USA) and performed according to manufacturer's instructions. For isolation of conditioned media, equal number of cells was seeded, and media was conditioned overnight. To remove cellular contaminant, conditioned media was collected and centrifuged at 300 g for 10 min in an Eppendorf Centrifuge 5424C (Eppendorf) at 4°C.
Antibody arrays
Proteome Profiler antibody arrays were purchased from R&D Systems and used according to the manufacturer's instructions. Conditioned media was generated as described above (ELISA). Imaging was performed on a FujiFilm LAS4000. Quantification of densitometry was achieved using the ImageQuantTL software (GE Healthcare).
Virus production and generation of stable cell lines HEK 293T cells were transfected with lentiviral expression constructs using Fugene 6 (Promega) in combination with pCMV-dR8.2 (gag/pol)and VSV-G (env) expression vectors using Fugene 6 (Promega). Viral stocks were collected 48 h posttransfection, filtered (0.45 μm) and placed on target cells for 8 h in the presence of 8 μg/ml polybrene. Forty-eight hours postinfection, cells were selected in the presence of puromycin (2 μg/ml).
RNA interference
Knockdown using scramble and/or gene-specific siRNA (ON-TARGET SMARTpool, Thermo Scientific) was performed using Lipofectamine RNAiMAX (Invitrogen). Stable knockdown was achieved using scramble and RECK-specific shRNA constructs (Thermo Scientific) to generate virus as above (see 'Virus production and generation of stable cell lines').
Chemotaxis assays
HUVEC cells were seeded on 12-well Boyden transwells in serum-free media (8 μm, BD Biosciences). Cells were allowed to migrate towards the indicated conditioned media for 24 h. Cells that did not migrate were removed using a cotton swab. The membranes were then fixed with methanol and stained with DAPI (4,6-diamidino-2-phenylindole). The number of migrated cells was determined by manual counting using an inverted Nikon TE2000E microscope (Nikon Instruments).
Invasion assays
Indicated cells were seeded in serum-free media on Matrigel-coated transwell inserts (8 μm, BD Biosciences). Complete media was placed below transwell inserts to encourage cell invasion. After 24 h, cells that did not invade were removed using a cotton swab. Membranes were then fixed with methanol and stained with DAPI. The number of invaded cells was determined by manual counting using an inverted Nikon fluorescent microscope.
IHC and analysis
The IHC detection of indicated antibodies was performed at Molecular Cytology Core Facility of MSKCC using Discovery XT processor (Ventana Medical Systems, Tucson, AR, USA). The tissue sections were deparaffinized with EZPrep buffer (Ventana Medical Systems), antigen retrieval was performed with CC1 buffer (Ventana Medical Systems) and sections were blocked for 30 min with Background Buster solution (Innovex, Richmond, CA, USA) (for rabbit, mouse and chicken antibodies, for rat and goat antibodies it should be 10% normal rabbit serum in phosphate-buffered saline+2% BSA (bovine serum albumin)). Antibodies were applied, and sections were incubated for 5 h, followed by 60 min incubation with biotinylated goat anti-rabbit IgG (Vector Laboratories, Burlingame, CA, USA, cat. no. PK6101) (biotinylated horse anti-mouse IgG (Vector Laboratories, cat. no. MKB-22258); biotinylated goat anti-chicken (Vector Laboratories, cat. no. BA-9010); biotinylated rabbit anti-goat IgG (Vector Laboratories, cat. no. BA-5000)) at 1:200 dilution. The detection was performed with DAB detection kit (Ventana Medical Systems) according to the manufacturer's instruction. Slides were counterstained with hematoxylin and coverslipped with Permount (Fisher Scientific, Waltham, MA USA). Staining quantification was performed using the MetaMorph software (MetaMorph, Nashville, TN, USA).
Immunofluorescence
Cells were grown as monolayer cultures on D-polylysine-coated coverslips and were fixed with 4% paraformaldehyde. After washing three times with phosphate-buffered saline, cells were blocked for 30 min with 10% goat serum and incubated overnight at 4°C with primary antibodies against RECK (1:50, R&D Systems). Cells were then stained with Alexa Fluor 563 secondary antibody (1:200, Invitrogen) for 1 h at room temperature. Stained sections and cells were mounted in ProLong Gold antifade reagent (Invitrogen) with DAPI. Images were taken on a Leica TCS SP5 confocal microscope (Leica Microsystems, Buffalo Grove, IL, USA).
Quantitative real-time PCR
Total RNA was isolated from cells using RNEasy Plus according to the manufacturer's instructions (Qiagen). cDNA was generated using 1 μg RNA and cDNA EcoDry Premix (Clontech, Mountain View, CA, USA). qRT-PCR was performed using a Realplex2 Mastercycler (Eppendorf) and analyzed by standard delta relative quantitation (ΔΔRQ). qRT-PCR parameters were as follows: initial denaturation at 95°C for 5 min, then 40 cycles of 95°C 15 s and 60°C 1 min. Primers used: RECK-Forward 5′-TGCAAGCAGGC ATCTTCAAA-3′ Reverse 5′-ACCGAGCCCATTTCATTTCTG-3′; and GAPDH-Forward 5′-AATGAAGGGGTCATTGATGG-3′ Reverse5′-AAGGTGAAGGTCG GAGTCAA-3′.
Endothelial tube formation assay
Endothelial cells (HUVEC) were resuspended in the indicated conditioned media and grown for 6 h on Matrigel (BD biosciences). Tube formation was quantified by calculating the average number of branch points in 10 fields of view. Imaging was performed using a Nikon TE2000-E inverted microscope. Representative images were chosen for publication from three replicates.
Immunoprecipitation
For immunoprecipitation, 50 μl of protein G magnetic beads (Pure-Proteome, Millipore) were crosslinked with 10 μg anti-RECK goat polyclonal antibody (R&D Systems) or goat polyclonal IgG antibody (R&D Systems) using 5 mM BS 3 according to the manufacturer's instructions (protocol guide, Millipore). Confluent Hs606T whole-cell lysates (500 μg total protein) were incubated with crosslinked beads at 4°C overnight with gentle agitation. The immunocomplexes were washed three times with TBS-T (0.1%), bound protein eluted in 60 μl 0.2 M glycine-HCl (pH 2.5) and neutralized using 5 μl of 1 M Tris (pH 8.5). Eluates were then used to probe an antibody array (Human Soluble Receptor Antibody Array, Non-Hematopoietic Panel, R&D Systems). This array was modified by using immunoprecipitated eluate instead of conditioned media or cell lysate. Eluates were also subjected to sodium dodecyl sulfatepolyacrylamide gel electrophoresis and western blotting analysis for RECK (goat antibody, R&D Systems), uPAR (goat antibody, R&D Systems), galectin-1 (rabbit antibody, Cell Signaling, Beverly, MA, USA), and integrin β1 (rabbit antibody, Cell Signaling).
Statistical analysis
For survival analysis, survival curves were analyzed using the Kaplan-Meier method and log rank test with the IBM Statistica 20 software (IBM, Road Armonk, NY, USA). All other statistical analysis was performed using the Prism 6 Software (GraphPad Software, La Jolla, CA, USA).
Kinexus antibody microarray
Protein lysates were sent to Kinexus Bioinformatics Corporation (Vancouver, BC, Canada) and profiled using their Kinex 850 Antibody Microarray (KAM). All samples were normalized according to the Kinexus normalization guidelines, and a list of downregulated candidate proteins was generated.
Microarray accession numbers
Gene Expression Omnibus (GEO)-accession number GSE56898. 
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